To explore the effect of esketamine on the dosage of opioids after gynecological surgery

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078386

Enrollment

Unknown

Registered

2023-12-07

Start date

2023-12-07

Completion date

Unknown

Last updated

2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecological operation

Interventions

Experimental group:0.2mg/kg esketamine load and intraoperative to0.2mg/kg/h intravenously pumped

Blank control group:The blank control group was treated with an equal amount of physiological saline, and the pump was stopped 30 minutes before the end of the surgery, and sufentanil was administered

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) ASA1-2 (2) Age 18-65 (3) Elective gynecological surgery in Shengjing Hospital (4)BMI: 18-30.

Exclusion criteria

Exclusion criteria: (1) Refusal to participate in the trial or use an intravenous pain relief pump (2) multiple primary malignancies(3) High blood pressure grade 3 and above (4) current and long-term use of opioids, psychotropic drugs, hormones, or non-drugsSteroidal anti-inflammatory drugs (5) have a history of chronic pain, epilepsy, schizophrenia, dementia (6) can not usePatient-controlled intravenous analgesia pump (7) Preoperative sleep disturbance or cognitive impairment

Design outcomes

Primary

Measure	Time frame
PCIA sufentanil consumption ;	—

Secondary

Measure	Time frame
PCIA sufentanil consumption ;VAS;sleep quality;	—

Countries

China

Contacts

Public ContactHang Xue

Shengjing Hospital affiliated to China Medical University

xuehang@sj-hospital.org+86 189 4025 6471

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026